

CURRICULUM VITAE (9/13)
DAVID F. RANSOHOFF, M.D.

Birthdate	[REDACTED]
Office Address	The University of North Carolina at Chapel Hill CB# 7080, 4103 Bioinformatics Bldg. Chapel Hill, NC 27599-7080 [REDACTED]
Current Position	Professor of Medicine Clinical Professor of Epidemiology
Home address	[REDACTED]
Marital Status	[REDACTED]
College	Harvard College, Cambridge, Mass.; B.A., [REDACTED]
Medical School	Case Western Reserve University School of Medicine Cleveland, Ohio; M.D., [REDACTED]
Internship in medicine:	Dartmouth-Hitchcock Medical Center Hanover, NH; [REDACTED]
Residency in medicine:	Dartmouth-Hitchcock Medical Center Hanover, NH; [REDACTED]
Fellowship	(clinical epidemiology) Robert Wood Johnson Clinical Scholars Program, Yale University, New Haven, CT; [REDACTED] (gastroenterology) University of Chicago, Chicago, Ill; [REDACTED]

Faculty positions: Assistant Professor of Medicine,
Assistant Professor of Epidemiology and Community Health
Case Western Reserve University School of Medicine
1979-85

Associate Professor of Medicine,
Associate Professor of Epidemiology and Biostatistics
Case Western Reserve University School of Medicine
1985-86

Associate Professor of Medicine and Epidemiology
Yale University School of Medicine
1986-91

Professor of Medicine
Clinical Professor of Epidemiology
University of North Carolina at Chapel Hill
1991-present

Robert Wood Johnson Clinical Scholars Program,
Co-Director or Director, UNC-CH, 1991-2001.

Clinical Research Curriculum (K30),
Director, UNC-CH, 1999-2010 (now merged into CTSA)

Licensure



New Hampshire, Vermont, Connecticut, Illinois, Ohio
North Carolina

Board Certification

American Board of Internal Medicine, 

American Board of Internal Medicine (Gastroenterology), 

Societies (p=past)

American College of Physicians (Fellow)

American Federation for Clinical Research (p)

American Gastroenterological Association

American Society for Gastrointestinal Endoscopy

Society for General Internal Medicine (p)

Society for Medical Decision Making (p) (Trustee, 1983-5; Vice-President, 1985-6)

National Advisory Committees (selected)

Department of Health and Human Services

- 1983-1990: NIDDK, Advisory Group on Data Systems
- 1985-8: Food and Drug Administration
 - Gastrointestinal Drugs Advisory Committee: 1985-8 (Chair: 1987-8)
- 1989 NIH: Consensus Development Conference, panel member
- 1989-1992: National Digestive Diseases Advisory Board: 1989-92
- 1994: National Cancer Institute, International Conference on Colon Cancer Screening, organizing committee
- 1999-2004: National Cancer Institute: National Survey of Colorectal Cancer Screening Practices, advisory panel
- 2000: National Cancer Institute: Colon cancer research PRG (progress review group)
- 2001: National Cancer Institute: Colon cancer screening - clinical research priorities
- 2002: NIH: Consensus Development Conference, panel member
- 2002: Food and Drug Administration
 - Gastrointestinal Drugs Advisory Committee Panelist, 2002: Colorectal Cancer Chemopreventive Agent Trial Design
- 2004: NCI, National Cancer Advisory Board: Development of a national biotechnology initiative for cancer
- 2006: NIH (Chair) State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control
- 2006: NIH Roadmap - Consultation Meeting, Bethesda MD, consultant
- 2010-12: Institute of Medicine: Committee to Review Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials
- 2010: NCI/CDC: Committee on Monitoring Colonoscopy Use in the United States
- 2012-16: FDA - consultant to Immunology Devices Panel, Center for Devices and Radiological Health

American Gastroenterological Association

- Council on Clinical Epidemiology: 1982-7 (Chairman 1982-7)

Robert Wood Johnson Foundation

- Advisory Committee, Care of Critically Ill Hospitalized Adult (SUPPORT): 1986-96

Institute of Medicine

- Workshop on thyroid cancer screening and health implications of exposure to radioactive iodine fallout, 1998
- Workshop on 'future of cancer diagnosis', 2003
- Workshop on 'developing cancer biomarkers', 2006
- Workshop on 'reviewing evidence to identify highly effective services', 2006
- Workshop on 'evidence generation for genomic diagnostic test development', 2010

Committee to Review Omics-Based Tests for Predicting Patient Outcomes in
Clinical Trials; member 2010-12

Journal Reviewer

American Journal of Medicine
Annals of Internal Medicine
Clinical Gastroenterology and Hepatology
Digestive Diseases and Sciences
Gastroenterology
Gut
Journal of the American Medical Association
Journal of Clinical Epidemiology
Journal of the National Cancer Institute
Nature
Nature Medicine
Nature Biotechnology
New England Journal of Medicine
Science
Science Translational Research

Editorial Responsibility

Editorial Boards

Medical Decision Making: 1984-5, 1987-9
Gastroenterology: 1987-1992
Journal of Clinical Epidemiology (and Journal of Chronic Disease): 1985-present
ACP Journal Club: 1991-present
American Journal of Medicine: 1997-present
Molecular Oncology: 2007-present
Molecular & Cellular Proteomics (Clinical Proteomics Advisory Committee): 2008-present

Associate Editor

Gastroenterology: 2001-2006
Journal of the National Cancer Institute: 2007-present

Honors and Awards

Alpha Omega Alpha

Henry J. Kaiser Family Foundation Faculty Scholar in General Internal Medicine:



Honorary Lectures

AOA Annual Lecture: The science of clinical medicine. Case Western Reserve
University School of Medicine, Cleveland, Ohio, 1989.

Walter B. Cannon Lecture: Colon cancer screening in the 1990s. Society of Gastrointestinal Radiologists. Scottsdale, Ariz., 1993.

Harrison Shull Visiting Professor, Vanderbilt University Medical Center, Nashville, TN, December, 1994.

Rupert B. Turnbull Memorial Lecturer, Washington University, St. Louis, MO, November, 1995.

Dartmouth Medical School Bicentennial Visiting Professor, Department of Medicine, Lebanon, NH, September 1997.

Gerald I. Plitman Distinguished Visiting Professor, Department of Medicine, University of Tennessee, Memphis, TN, April 1998.

O. Roger Hollan Visiting Professor, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, January 1999.

Rammelkamp Visiting Professor, Department of Medicine, Cleveland Metropolitan General Hospital, Case Western Reserve University School of Medicine, Cleveland OH, January 2000.

Royal College of Surgeons of Edinburgh Quincentenary Lecture, Edinburgh Scotland, November 2005.

The 20th Ben Abelson Memorial Lecture, Washington University, St. Louis MO, April 2007.

NIH: Inaugural seminar in new NIH seminar series ('Mind the gap'). Chaos in the brickyard: Translational research in 2007. Bethesda, MD. November 2007.

NIH: Great teachers series. Evidence-based medicine: A story of evidence, policy, and politics. NIH Clinical Center Grand Rounds. Bethesda MD. January 2009

BIBLIOGRAPHY

Publications (* indicates that an editorial accompanied the article)

1. Ransohoff DF, Feinstein AR. Is decision analysis useful in clinical medicine? [Editorial] *Yale J Biol Med* 1976; 49:165-8.
- *2. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. *N Engl J Med* 1978; 299:926-30.
3. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. *Gastroenterology* 1981; 80:816-9.
4. Ransohoff DF, Muir WA. Diagnostic work-up bias in the evaluation of a test: serum ferritin and hereditary hemochromatosis. *Med Decis Making* 1982; 2:139-45.
5. Dworken HJ, Ransohoff DF. Why classify inflammatory bowel disease? [Editorial] *Ann Intern Med* 1982; 97:273-4.
- *6. Gracie WA, Ransohoff DF. The natural history of silent gallstones: the innocent gallstone is not a myth. *N Engl J Med* 1982; 307:798-800.
7. Yardley JH, Ransohoff DF, Riddell RH, Goldman H. Cancer in inflammatory bowel disease: how serious is the problem and what should be done about it? [Editorial] *Gastroenterology* 1983; 85:197-200.
8. Ransohoff DF, Gracie WA, Wolfenson LB, Neuhauser D. Prophylactic cholecystectomy or expectant management for persons with silent gallstones: a decision analysis to assess survival. *Ann Intern Med* 1983; 99:199-204.
9. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardley JH. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* 1983; 14:931-68.
10. Clemens JD, Ransohoff DF. A quantitative assessment of pre-dental antibiotic prophylaxis for patients with mitral-valve prolapse. *J Chronic Dis* 1984; 37:531-44.
11. Littenberg B, Ransohoff DF. Hepatitis B vaccination: three decision strategies for the individual. *Am J Med* 1984; 77:1023-6.
12. Ransohoff DF, Riddell RH, Levin B. Ulcerative colitis and colonic cancer: problems in assessing the diagnostic usefulness of mucosal dysplasia. *Dis Colon Rectum* 1985; 28:383-8.

13. Arbesman H, Ransohoff DF. Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. *JAMA* 1987; 257:516-8.
14. Ransohoff DF, Miller GF, Forsythe SB, Hermann RE. Outcome of acute cholecystitis in patients with diabetes mellitus. *Ann Intern Med* 1987; 106:829-32.
15. Ransohoff DF. Colon cancer in ulcerative colitis. [Editorial] *Gastroenterology* 1988; 94:1089-91.
16. Sawyer J, Ellner JJ, Ransohoff DF. To biopsy or not to biopsy in suspected herpes simplex encephalitis: a quantitative analysis. *Med Decis Making* 1988;8:95-101.
17. Horwitz RI, Ransohoff DF. Epidemiologic methods and methodologic vigilance. [Editorial] *J Gen Intern Med*; 1988; 3:298-9.
18. Boyer JL, Ransohoff DF. Is colchicine effective therapy for cirrhosis? [Editorial] *N Engl J Med* 1988; 318:1751-2.
19. Imperiale TF, Ransohoff DF. Aortic stenosis, idiopathic gastrointestinal bleeding, and angiodysplasia. *Gastroenterology* 1988; 95:1670-6.
20. King CH, Lombardi G, Lombardi C, et al. Chemotherapy-based control of schistosomiasis hematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. *Am J Trop Med Hyg* 1988; 39:295-305.
21. Ransohoff DF, Gracie WA. Management of patients with symptomatic gallstones: a quantitative analysis. *Am J Med* 1990; 88:154-60.
- *22. Ransohoff DF, Lang CA. Small adenomas detected during fecal occult blood test screening for colorectal cancer: the impact of serendipity. *JAMA* 1990; 264:76-78.
23. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. *Lancet* 1990; 336:542-5.
24. Heald AE, Ransohoff DF. Needlestick injuries among resident physicians. *J Gen Intern Med* 1990; 5:389-393.
25. Ransohoff DF, Lang CA, Kuo HS. Colonoscopic surveillance after polypectomy: considerations of cost effectiveness. *Ann Intern Med* 1991; 114:177-182.
26. Ransohoff DF, Lang CA. Screening for colorectal cancer. *N Engl J Med* 1991;325:37-41.

27. Wright J, McGeer A, Chyatte D, Ransohoff DF. Mechanisms of glove tears and sharp injuries among surgical personnel. JAMA 1991; 266:1668-71.
28. Rabeneck L, Ransohoff DF. Is Helicobacter pylori a cause of duodenal ulcer? A methodologic critique of current evidence. Am J Med 1991;91:566-72.
- *29. Ransohoff DF, Lang CA. Sigmoidoscopic screening in the 1990s. JAMA 1993;269:1278-81.
30. Ransohoff DF. Gastroenterology. JAMA 1993; 270: 206-9.
31. Ransohoff DF, Gracie WA. Treatment of gallstones. Ann Intern Med 1993; 119: 606-19.
32. Ransohoff DF, Gracie WA, Schmittner JP. Guidelines of the American College of Physicians for the treatment of gallstones. Ann Intern Med 1993; 119: 620-2.
33. Wright JG, McGeer AJ, Chyatte D, Ransohoff DF. Exposure rates to patients' blood for surgical personnel. Surgery 1993; 114: 897-901.
34. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? JAMA 1994; 271: 1011-3.
35. Ransohoff DF, Lang CA. Using colonoscopy to screen for colorectal cancer [editorial]. Am J Gastroenterol 1994; 89: 1765-6.
36. Ransohoff DF, McSherry CK. Why are cholecystectomy rates increasing? [editorial] JAMA 1995; 273: 1621-2.
37. Ransohoff DF, Lang CA. Improving the fecal occult blood test [editorial]. N Engl J Med 1996;334: 189-90.
38. Otchy DP, Ransohoff DF, Wolff BG, Weaver A, Ilstrup D, Carlson H, Rademacher D. Metachronous colon cancer in persons who have had a large adenomatous polyp. Amer J Gastroenterol 1996;91: 448-454.
39. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med 1997; 126:811-22.
40. American College of Physicians. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med 1997; 126:808-10.
41. Collins MMcN, Ransohoff DF, Barry MJ. Early detection of prostate cancer: serendipity strikes again. JAMA 1997; 278: 1516-9.

42. Ransohoff DF, Harris RP. Lessons from the mammography screening controversy: can we improve the debate? *Ann Intern Med* 1997; 127: 1029-34.
43. Lang CA, Ransohoff DF. On the sensitivity of fecal occult blood test screening for colorectal cancer [editorial]. *JNCI* 1997; 89:1392-3.
44. Lang CA, Ransohoff DF. What can we conclude from the randomized controlled trials of fecal occult blood test screening? *Eur J Gastroenterol & Hepatol* 1998; 10:199-204.
45. Schoenfeld PS, Cash B, Kita J, Piorkowski M, Creuss D, Ransohoff D. Effectiveness and patient satisfaction with screening flexible sigmoidoscopy performed by registered nurses. *Gastrointest Endos* 1999; 49:158-62
46. Cash BD, Schoenfeld PS, Ransohoff DF. Licensure, use, and training of paramedical personnel to perform screening flexible sigmoidoscopy. *Gastrointest Endos* 1999; 49:163-9.
47. Ransohoff, DF. Economic impact of surveillance. *Gastrointest Endos* 1999; 49: S67-71.
48. Shaheen NJ, Ransohoff DF. Sigmoidoscopy costs and the limits of altruism [editorial]. *Am J Med* 1999; 107:286-7.
49. Hunt JP, Baker CC, Fakhry SM, Rutledge RR, Ransohoff D, Meyer AA. Accuracy of administrative data in trauma. *Surgery* 1999; 126: 191-7.
- *50. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. *N Engl J Med* 2000;343:169-74.
51. Shaheen NJ, Crosby MA, O'Malley MS, Murray SC, Sandler RS, Galanko JA, Ransohoff DF, Klenzak JS. The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening. *Amer J Gastroenterol* 2000; 95:3259-65.
52. Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. *Amer J Gastroenterol* 2000; 95:3250-8.
53. Ransohoff DF, Ransohoff RM. Sensationalism in the media: when scientists and journalists may be complicit collaborators. *Eff Clin Pract* 2001;4:185-88.
- *54. Ashley OS, Nadel M, Ransohoff DF. Achieving quality in flexible sigmoidoscopy screening for colorectal cancer. *Am J Med* 2001;111:643-53.

55. Ransohoff DF, Sandler RS. Screening for colorectal cancer. *N Engl J Med* 2002;346:40-4.
56. Ransohoff DF. Lessons from the UK sigmoidoscopy screening trial. *Lancet* 2002; 359: 1266-7.
57. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. *JAMA* 2002;287:1972-81.
58. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Clinical applications. *JAMA* 2002;287:1982-86.
59. Ransohoff DF. Research opportunity at the interface of molecular biology and clinical epidemiology. *Gastroenterology* 2002; 122:1199.
60. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Results of screening colonoscopy among persons 40 to 49 years of age. *N Engl J Med* 2002;346: 1781-5.
- *61. Ransohoff DF, Collins MM, Fowler FJ, Jr. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. *Am J Med* 2002; 113:663-7
62. Ransohoff, DF. Challenges and opportunities in evaluating diagnostic tests. *J Clin Epid* 2002; 55:1178-82.
63. Ransohoff DF. Screening colonoscopy in balance. Issues of implementation. *Gastroenterol Clin North Am* 2002; 31:1031-44, vii.
64. Ransohoff DF. Developing molecular biomarkers for cancer. *Science* 2003; 299: 1679-80.
65. Corbie-Smith G, St George DM, Moody-Ayers S, Ransohoff DF. Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. *J Clin Epidemiol* 2003; 56:416-20.
66. Ransohoff DF. Discovery-based research and fishing. *Gastroenterology* 2003; 125:290.
- *67. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. *Ann Intern Med* 2003;139:959-65.
68. Corbie-Smith G, Miller WC, Ransohoff DF. Interpretations of 'appropriate' minority inclusion in clinical research. *Am J Med* 2004; 116:249-52.

69. Ransohoff DF. Rules of evidence for cancer molecular marker discovery and validation. *Nat Rev Cancer* 2004; 4: 309-14.
70. Ransohoff DF. Virtual colonoscopy: what can it do vs what will it do. *JAMA* 2004; 291: 1772-4.
71. Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. *Ann Intern Med* 2004; 141:264-71
72. Ransohoff DF. Evaluating discovery-based research: When biologic reasoning cannot work. *Gastroenterology* 2004; 127:1028.
- *73. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med* 2004; 351:2704-14.
- *74. Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, Ransohoff DF. A national survey of primary care physicians' methods for screening for fecal occult blood. *Ann Intern Med* 2005; 142:86-94.
75. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. *Nat Rev Cancer* 2005; 5:142-9.
76. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. *J Natl Cancer Inst* 2005; 97:315-9.
77. Ransohoff DF. Colon cancer screening in 2005: status and challenges. *Gastroenterology*. 2005;128(6):1685-95.
78. Ransohoff DF. CON: Immediate colonoscopy is not necessary in patients who have polyps smaller than 1 cm on computed tomographic colonography. *Am J Gastroenterol*. 2005;100(9):1905-7.
79. Klabunde CN, Lanier D, Breslau ES, Zapka JG, Fletcher RH, Ransohoff DF, et al. Improving colorectal cancer screening in primary care practice: innovative strategies and future directions. *J Gen Intern Med* 2007;22(8):1195-205
80. Lieberman D, Nadel M, Smith RA, Atkin W, Duggirala SB, Fletcher R, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc* 2007;65(6):757-66.
81. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. *J Natl Cancer Inst* 2007;99(19):1462-1470.

82. Ransohoff DF. What is the role of iFOBT in screening for colorectal cancer? *Gut* 2007;56(10):1343-1344.
83. Schenck AP, Klabunde CN, Warren JL, Peacock S, Davis WW, Hawley ST, et al. Data sources for measuring colorectal endoscopy use among Medicare enrollees. *Cancer Epidemiol Biomarkers Prev* 2007;16(10):2118-2127
84. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gotzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the Evidence for Lung Cancer Screening: The International Early Lung Cancer Action Program (I-ELCAP) Study. *Arch Intern Med* 2007;167(21):2289-2295.
85. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. *J Clin Epidemiol* 2007;60(12):1205-1219.
86. Ransohoff DF. Response to commentary. *J Clin Epidemiol* 2007;60(12):1226-1228.
87. Schenck AP, Klabunde CN, Warren JL, Peacock S, Davis WW, Hawley ST, et al. Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among Medicare enrollees in fee for service. *Cancer Epidemiol Biomarkers Prev* 2008;17(4):799-804.
88. Ransohoff DF, Martin C, Wiggins WW, Hitt BA, Keku TO, Galanko JA, et al. Assessment of serum proteomics to detect large colon adenomas. *Cancer Epidemiol Biomarkers Prev* 2008;17: 2188-93.
89. Kudo S, Lambert R, Allen JL, Fujii H, Fujii T, Kashida H, et al. Nonpolypoid neoplastic lesions of the colorectal mucosa. *Gastrointest Endosc* 2008;68(4 Suppl):S3-47
90. Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF, Brown ML. Implications of new colorectal cancer screening technologies for primary care practice. *Med Care* 2008;46(9 Suppl 1):S138-146
91. Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after a negative screening colonoscopy. *N Eng J Med* 2008;359:1218-24.
92. Ransohoff DF. The process to discover and develop biomarkers for cancer: a work in progress. *J Natl Cancer Inst* 2008;100(20):1419-1420
93. Ransohoff DF. How much does colonoscopy reduce colon cancer mortality? *Ann Intern Med* 2009;150(1):50-2.

94. Imperiale TF, Glowinski EA, Juliar BE, Azzouz F, Ransohoff DF. Variation in polyp detection rates at screening colonoscopy. *Gastrointest Endosc* 2009;69(7):1288-95
95. Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, Ransohoff DF. Adverse events following outpatient colonoscopy in the Medicare population. *Ann Intern Med* 2009;150:849-57.
96. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurement of proteins in plasma. *Nat Biotechnology* 2009;27(7):633-41.
97. Khoury MJ, McBride C, Schully SD, Ioannidis JPA, Geero WG, Janssens ACJW, et al. The scientific foundation for personal genomics: recommendations from an NIH-CDC multidisciplinary workshop. *Genet Med* 2009;11(8):559-67.
98. Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, et al. Protein-Based Multiplex Assays: Mock Presubmissions to the US Food and Drug Administration. *Clin Chem* 2010;56(2):165-171.
99. Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. *Clin Chem* 2010;56(2):237-243
100. Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. *Eur J Clin Invest* 2010;40(1):64-68.
101. Ransohoff DF. Proteomics research to discover markers: what can we learn from Netflix? *Clin Chem* 2010;56(2):172-176.
102. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. *J Clin Oncol* 2010;28(4):698-704.
103. Imperiale TF, Ransohoff DF. Understanding differences in the guidelines for colorectal cancer screening. *Gastroenterology* 2010;138(5):1642-1647
104. Ransohoff DF. Can endoscopy protect against colorectal cancer? An RCT. *Lancet* 2010;375(9726):1582-1584.
105. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. *Semin Oncol* 2010;37(3):202-15.
106. Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn

DM, Wright CF, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of Genetic Risk Prediction Studies (GRIPS): explanation and elaboration. *J Clin Epidemiol* 2011.

107. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. *Cancer Prev Res (Phila)* 2011;4(3):375-383.
108. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, et al. Biomarker studies: a call for a comprehensive biomarker study registry. *Nat Rev Clin Oncol* 2011;8(3):171-176.
109. Ransohoff DF, Yankaskas B, Gizlice Z, Gangarosa L. Recommendations for post-polypectomy surveillance in community practice. *Dig Dis Sci* 2011;56(9):2623-2630.
110. Pignone M, Ransohoff DF. Cross-model comparisons to improve the value of modeling: the case of colorectal cancer screening. *Med Decis Making* 2011;31(4):524-526.
111. Brawley O, Byers T, Chen A, Pignone M, Ransohoff D, Schenk M, Smith R, Sox H, Thorson AG, Wender R. New American Cancer Society process for creating trustworthy cancer screening guidelines. *JAMA* 2011;306(22):2495-2499
112. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE. Bone-density testing interval and transition to osteoporosis in older women. *N Engl J Med* 2012;366(3):225-233.
113. Imperiale TI, Ransohoff DF. Risk of colorectal cancer in persons with a family history of adenomatous polyps: A systematic review of the literature. *Ann Intern Med* 2012; 156(10):703-709.
114. Zapka J, Klabunde CN, Taplin S, Yuan G, Ransohoff D, Kobrin S. Screening Colonoscopy in the US: Attitudes and Practices of Primary Care Physicians. *J Gen Intern Med* 2012;27(9):1150-1158.
115. Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF. Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. *Am J Med* 2012;125(12):1181-1187.
116. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF, for the Presept Clinical Study Steering Committee I, Study T. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut* 2013.

117. Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. *JAMA* 2013;309(2):139-140.
118. European Colorectal Cancer Screening Guidelines Working G, von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013;45(1):51-59.
119. Khoury MJ, Janssens AC, Ransohoff DF. How can polygenic inheritance be used in population screening for common diseases? *Genet Med* 2013
120. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OL, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. *Cancer Epidemiol Biomarkers Prev* 2013;22(4):508-516.
121. Ransohoff DF. Cultivating cohort studies for observational translational research. *Cancer Epidemiol Biomarkers Prev* 2013;22(4):481-484.

Book Chapters

1. Feinstein AR, Ransohoff DF. Problems of compliance as a source of bias in data analysis. In: McMahon FG, ed. Patient compliance, Volume XI, Principles and techniques of human research and therapeutics. Mt. Kisco, NY: Futura Publ Co, 1976: 65-76.
2. Gracie WA, Ransohoff DF. The silent gallstone: requiescat in pace. In: Delaney JP, Varco RL, eds. Controversies in surgery II. Philadelphia: WB Saunders, 1983: 361-72.
3. Ransohoff DF, Gracie WA. Asymptomatic gallstones. In: Cameron JL, ed. Current surgical therapy 1984-1985. Philadelphia: BC Decker, 1984: 182-4.
4. Ransohoff DF. Long-term natural history of silent gallstones: implications for secondary prevention. In: Capocaccia L, Ricci G, Angelico F, Angelico M, Attili AF, eds. Epidemiology and prevention of gallstone disease. Lancaster: MTP Press, 1984: 199-206.
5. Gracie WA, Ransohoff DF. Natural history and expectant management of gallstone disease. In: Cohen S, Soloway RD, eds. Gallstones. New York: Churchill Livingstone, 1985: 27-43.
6. Ransohoff DF. Natural history of silent gallstones. In: Paumgartner G, Stiehl A, Gerok W. Enterohepatic circulation of bile acids and sterol metabolism (Falk Symposium, 42nd; 1984: Bern, Switzerland). Lancaster: MTP Press, 1985: 277-84.
7. Ransohoff DF. Science and diagnosis. In: Vig PS, Ribbens KA, eds. Science and clinical judgment in orthodontics. (Monograph 19, Craniofacial Growth Series). Center for Human Growth and Development, The University of Michigan, Ann Arbor, 1986: 61-73.
8. Ransohoff DF, Gracie WA. Asymptomatic gallstones. In: Cameron JL, ed. Current surgical therapy 1984-1985. Philadelphia: BC Decker, 1984: 182-4.
9. Ransohoff DF. Cholelithiasis: medical and surgical aspects. In: Bayless TM, ed. Current therapy in gastroenterology and liver disease. Toronto: BC Decker, 1990:519-21.
10. Ransohoff DF. Natural history of gallstone disease and implications for non-surgical therapy. In: Paumgartner G, Barbara L, Stiehl A, Roda E, eds. Strategies for the treatment of hepatobiliary diseases. Dordrecht: Kluwer Academic Publishers, 1990: 119-23.

11. Ransohoff DF. Methodologic challenges in studying markers for colon cancer in ulcerative colitis. In: Riddell RH, ed. Dysplasia and cancer in colitis. New York: Elsevier, 1991, 75-8.
12. Talley NJ, Nyren O, Drossman DA, Heaton KW, Veldhuyzen van Zanten SJO, Koch MM, Ransohoff DF. The irritable bowel syndrome: toward optimal design of controlled treatment trials. *Gastroenterology International* 1993; 6:189-211.
13. Ransohoff DF. Colorectal cancer. In: Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, pp 205-224.
14. Lang CA, Ransohoff DF. Defining risk for colorectal cancer. In: Young G, Levin B, Rozen P, eds. Prevention and early detection of colorectal cancer. London: W B Saunders and Co., 1996: 155-70.
15. Ransohoff, DF. Surveillance and cancer risk in ulcerative colitis: overview of methodological issues. In: McLeod, R, ed. Trends in inflammatory bowel disease therapy 1996. Lancaster, UK: Kluwer, 1997, 224-9.

Letters, Miscellaneous

1. Ford AB, Ransohoff DF. The use of non-physician personnel in the delivery of primary care. Report for the Ohio Comprehensive Health Planning Council, 1971, 84 pp.
2. Ransohoff DF. The logic of medicine, by EA Murphy. *Am Scientist* 1976; 64: 698.
3. Ransohoff DF. Pharyngitis and decision analysis. *Ann Intern Med* 1977; 87: 249.
4. Ransohoff DF. Lactose intolerance and recurrent abdominal pain in childhood. *Gastroenterology* 1980; 78: 182.
5. Ransohoff DF. More on gastric lesions, aspirin, and rheumatic disease. *Gastroenterology* 1980; 78: 872-3.
6. Ransohoff DF. More on radionuclide scanning in the diagnosis of acute cholecystitis. *Gastroenterology* 1980; 79: 401.

7. Ransohoff DF. Does UGI endoscopy affect decision making? *Gastroenterology* 1980; 79: 1342.
8. Ransohoff DF. Real-time ultrasonography in the diagnosis of gallbladder disease. *Gastroenterology* 1981; 80: 872-3.
9. Ransohoff DF. Pancreatic cancer and coffee. *Gastroenterology* 1981; 81: 399-400.
10. Ransohoff DF. More visible vessels and recurrent upper gastrointestinal bleeding. *Gastroenterology* 1982; 82: 993-4.
11. Gracie WA, Ransohoff DF. Innocent gallstones. *N Engl J Med* 1983; 308: 222-3.
12. Ransohoff DF. Colonic polyps and acromegaly - are they associated? *Gastroenterology* 1983; 84: 193.
13. Dworken HJ, Ransohoff DF. Classifying inflammatory bowel disease. *Ann Intern Med* 1983; 98: 412.
14. Ransohoff DF, Weber FL. Hepatitis B vaccine and cost-effectiveness analysis. *Gastroenterology* 1983; 84: 877.
15. Ransohoff DF, Gracie WA, Wolfenson LB, Neuhauser D. Silent gallstones. *Ann Intern Med* 1983; 99: 876-7.
16. Ransohoff DF. Cancer surveillance in ulcerative colitis. *Gastroenterology* 1984; 86: 770-1.
17. Ransohoff DF. Natural history of cholelithiasis. *Gastroenterology* 1985; 88: 848.
18. Ransohoff DF. Prevention. *JAMA* 1986; 256: 3161.
19. Ransohoff DF. Dating gallstones. *Hepatology* 1987; 7: 401-2.
20. Ransohoff DF, Miller GL, Forsythe SB, Herman RE. Asymptomatic gallstones in diabetic persons. *Ann Intern Med* 1987; 107: 942.
21. Ransohoff DF. Folate supplementation in ulcerative colitis. *Gastroenterology* 1990; 98: 544.
22. Ransohoff DF, Lang CA. Screening for colorectal cancer. *N Engl J Med* 1992; 326: 136-7.
23. Wright JG, Ransohoff DF. Glove tears and sharp injuries in surgical personnel. *JAMA* 1992; 267: 924.

24. Ransohoff DF. Less costly colon procedure. Washington Post Health, Vol. 9, Number 24, June 15, 1993, page 4, col 4.
25. Ransohoff DF, Gracie WA. Is gallbladder function a predictor of outcome? Ann Intern Med 1994; 120: 523-4.
26. Ransohoff DF. Helicobacter pylori and duodenal ulcer, gastric cancer, and nonulcer dyspepsia: a review. Ann Intern Med 1994; 120 (Suppl 3): 62-3.
27. Lang CA, Ransohoff DF. Screening for colorectal cancer: which test is best? JAMA 1994; 272:1100.
28. Ransohoff DF. The case for colorectal cancer screening. Hosp Pract Off Ed 1994; 29: 25-32.
29. Cotton PB, Chung SC, Davis WZ, Gibson RM, Ransohoff DF, Strasberg SM. Issues in cholecystectomy and management of duct stones. Am J Gastroenterol 1994; 89: S169-76.
30. Ransohoff DF, Lang CA. Improving the fecal occult-blood test. N Engl J Med 1996; 334: 1608.
31. Ransohoff DF, Lang CA, Young GP. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 113:1423-4.
32. Imperiale TF, Ransohoff DF. Colon cancer screening. N Engl J Med 2000; xxx:yyyy.
33. Ransohoff DF, Pignone M. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2001; 344: 1022-3.
34. Ransohoff DF, Sandler, RS. Screening for colorectal cancer. N Engl J Med 2002;346:1672-4.
35. Imperiale TF, Ransohoff DF. Screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002;347:1205-6.
36. Ransohoff, DF. Fecal DNA tests for colorectal cancer. N Engl J Med 2002;346:1912-3.
37. Ransohoff DF. Gene-expression signatures in breast cancer. N Engl J Med 2003; 348:1715-7; author reply -7.
38. Imperiale TF, Ransohoff DF, Itzkowitz SH. Fecal DNA for colorectal-cancer screening. N Engl J Med 2005; 352:1384-5.

39. Fletcher RH, Ransohoff DF, Imperiale TF. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. *Cancer* 2007.

SELECTED INVITED PRESENTATIONS (* indicates moderator or organizer)

1. Problems of compliance as a source of bias in data analysis. Tulane Therapeutics Symposium, New Orleans, Louisiana, November, 1975.
2. Inter-observer variability for dysplasia in ulcerative colitis: a progress report. Workshop, American Gastroenterological Association. New Orleans, Louisiana, May, 1979.
3. Diagnostic work-up bias in the evaluation of a test: serum ferritin and hereditary hemochromatosis. Sydenham Society, Washington, DC, May, 1980.
4. The natural history of silent gallstones: Postgraduate course, American Association for the Study of Liver Diseases, Chicago, Illinois, November, 1983.
5. Long-term natural history of silent gallstones: implications for secondary prevention. International Workshop on the Epidemiology and Prevention of Gallstone Disease, Rome, Italy, December, 1983.
6. Natural history of silent gallstones. VIII International Bile Acid Meeting. Falk Symposium No. 42, Berne, Switzerland, September, 1984.
7. Science and diagnosis. Moyers Symposium. Ann Arbor, Michigan, March, 1985.
8. Role of epidemiology in patient management: gallstones. National Institutes of Health - Opportunity for Epidemiological Research in the Gastrointestinal Diseases. Mayo Clinic, Rochester, Minnesota, May, 1987.
9. Management of gallstone disease. Annual Course, Society for Surgery of the Alimentary Tract, May, 1988.
10. The science of clinical medicine. AOA Annual Lecture, Case Western Reserve University School of Medicine, Cleveland, Ohio, 1989.
11. Lithotripsy management of gallstone disease. American College of Physicians national meeting, San Francisco, California, April, 1989.
12. Scientific standards for studies of colon cancer risk in ulcerative colitis. National Foundation for Ileitis and Colitis advisory meeting, Baltimore, Maryland May, 1989.

13. Natural history of gallstones and implications for non-surgical management. Falk Symposium No.53, Lugano, Switzerland, June, 1989.
14. Development of disease definitions and severity indices. National Institutes of Health, Digestive Disease Advisory Board, Bethesda, Maryland, July, 1990.
15. Is fecal occult blood testing useful? 8th National Postgraduate Course, American Society for Gastrointestinal Endoscopy, San Diego, California, February, 1991.
16. Is surveillance colonoscopy appropriate after removal of colonic adenomas? 8th National Postgraduate Course, American Society for Gastrointestinal Endoscopy, San Diego, California, February, 1991.
17. Ransohoff DF. Screening for colorectal cancer: challenges in the 1990s. American Cancer Society, Atlanta, Georgia, January, 1992.
18. Ransohoff DF. Clinical epidemiology research in gastroenterology. National Digestive Diseases Advisory Board. Bethesda, Md., January, 1992.
19. Colon cancer screening in the 1990s: challenges and opportunities. St. Mark's Hospital. London, April, 1992.
20. Colon cancer screening in the 1990s: challenges and opportunities. American Gastroenterological Association national meeting. San Francisco, May, 1992.
21. Colon cancer screening in the 1990s. Walter B. Cannon Lecture; Society of Gastrointestinal Radiologists. Scottsdale, Arizona, January, 1993.
22. Colon cancer screening in the 1990s. National Cancer Institute, Division of Cancer Prevention and Control. Rockville, Md., January, 1993.
23. Lessons for conducting epidemiologic research: an assessment of 30 years of research on colon cancer screening. Department of Epidemiology, University of North Carolina at Chapel Hill, March, 1993.
24. Colon cancer screening. American College of Physicians national meeting. Washington, DC, April, 1993.
25. An agenda for research on colon cancer screening. Harvard School of Public Health. Boston, Mass., April, 1993.
25. Colon cancer screening in the 1990s. Society for General Internal Medicine national meeting. Washington, DC, May, 1993.
26. Is fecal occult blood test screening worthwhile? National Meeting of the American Society for Gastrointestinal Endoscopy. Boston, Mass., May, 1993.

27. Colon cancer screening and surveillance: importance of definitions. National Digestive Diseases Advisory Board, Bethesda, Md., July, 1993.
28. Colon cancer screening and surveillance: research challenges and opportunities. National Digestive Diseases Advisory Board, Bethesda, Md., July, 1993.
29. Colon cancer screening- research challenges and opportunities. National Cancer Institute, Division of Cancer Prevention and Control. Rockville, Md., July, 1993.
30. Colon cancer screening in the 1990s. Annual Clinical Conference (Advances in the Biology and Therapy of Colorectal Cancer) MD Anderson Cancer Center, The University of Texas, Houston, Tx, November, 1993.
31. Colon cancer screening in the 1990s. Harvard Medical School, Brigham and Women's Hospital, Boston, Mass., December 1993.
32. Issues in research on colon cancer screening. Harvard School of Public Health, Boston, Mass., December 1993.
33. Risks and benefits of colon cancer screening. American College of Physicians national meeting, Miami, Fla, April 1994.
34. Surveillance following colonoscopic polypectomy. American Gastroenterological Association national meeting, New Orleans, La. May 1994.
35. * Current screening and detection methods. National Cancer Institute (International Workshop on Colorectal Cancer Screening), Bethesda, MD. June 1994.
36. Screening for colon cancer. Vanderbilt Medical School, Memphis, Tenn. December 1994.
37. Screening and surveillance for colorectal cancer. Duke Univ. Med. Center, Durham, NC. January 1995.
38. Decision-making in colon cancer. Washington Univ., St. Louis. January 1995.
39. Colon cancer screening in the 1990s. Society for General Internal Medicine national meeting. San Diego, Calif. May, 1995.
40. Economic issues in evaluating a new technology. National Cancer Institute (Workshop on Virtual Colonoscopy), Bethesda, MD. June 1995.
41. (1) Epidemiology, risk factors, and objectives of screening.
(2) Cost effectiveness of colon cancer screening. International Union Against Cancer (UICC), Genoa, Italy. September 1995.

42. Secondary prevention of colon cancer: controversies and consensus. National Conference on Colorectal Cancer, American Cancer Society, Chicago, Ill. November 1995.
43. (1) Screening for colorectal neoplasia.
(2) Medical, legal and ethical issues of screening practices. Rupert B. Turnbull Memorial Lecture in Surgery, Washington Univ., St. Louis. November 1995.
44. The science of clinical medicine. Surgery Grand Rounds. Washington Univ., St. Louis. November 1995.
- 45.* Ulcerative colitis and Crohn's disease: health status scales for research and clinical practice. American Gastroenterological Association Symposium: Outcomes Research in GI Disease, at University of North Carolina, Chapel Hill NC. March 1996.
- 46.* Use of diagnostic tests in pharmacoepidemiology. CePOR '96: Efficacy versus effectiveness; The Center for Pharmaceutical Research, Chapel Hill NC. April 1996.
47. Colon cancer screening in the 1990s: Current controversies. Cincinnati Society of Internal Medicine, Cincinnati, Ohio. April 1996.
48. The science of clinical medicine. Medical Grand Rounds, University of Cincinnati, Cincinnati, Ohio. April 1996.
49. Controversies in colon cancer screening. American College of Physicians national meeting, San Francisco, Calif. April 1996.
50. Colon cancer screening in the 1990s. Society for General Internal Medicine national meeting. Washington, DC, May, 1996.
- 51.* Family history in assessing colorectal cancer risk. Symposium at American Gastroenterological Association national meeting. San Francisco, Calif. May 1996.
52. Surveillance and cancer risk in ulcerative colitis: overview of methodological issues. Trends in inflammatory bowel disease therapy 1996, The Canadian Association of Gastroenterology and the Canadian Society of Colon and Rectal Surgeons, Ottawa, Ontario. June 1996.
53. Cost-effectiveness of colon cancer screening. Second Annual Southeastern Gastroenterology Symposium. Savannah, Ga. October 1996.
54. Organization and Preparation of Scientific Presentations. AAMC Minority Faculty Career Development Seminar. Association of American Medical Colleges, Bethesda, Md. October 1996.

55. Current controversies in colon cancer screening. National Naval Medical Center, Bethesda, Md. October 1996.
56. (1) Current controversies in colon cancer screening
(2) What have we learned from randomized clinical trials of fecal occult blood testing? University of Alabama at Birmingham, Birmingham, Ala. February 1997.
57. What have we learned from randomized clinical trials of fecal occult blood testing? University of Calgary, Kananaskis, Alberta. February 1997.
58. Controversies in colon cancer screening. American College of Physicians national meeting, Philadelphia, Pa. March 1997.
59. Clinical science and the colon cancer screening controversy. Dartmouth Medical School and Hitchcock Medical Center, Lebanon, NH. September 1997.
60. Problems of risk perception in the mammography screening controversy. Center for Clinical Evaluative Sciences, Dartmouth Medical School, Hanover, NH. September 1997.
61. Controversies in colon cancer screening. American College of Surgeons national meeting, postgraduate course. Chicago, Ill. October 1997.
62. Screening for colorectal cancer. Tenth International Course on Therapeutic Endoscopy. Toronto, Ont. October 1997.
63. (1) Balancing enthusiasm and caution in screening for colorectal cancer.
(2) Weighing the risks and benefits of prophylactic aspirin therapy to prevent colon cancer. 6th United European Gastroenterology Week. Birmingham, UK. October 1997.
64. Colon cancer screening in the 1990's. Southern Medical Association Annual Scientific Assembly. Charlotte, NC. November 1997.
- 65.* At the interface of science and policy: the mammography screening debate. Clinical Scholars Program national meeting, Ft. Lauderdale, Florida, November 1997.
66. Colon cancer screening in the 1990's. The year in internal medicine; Northwestern University Medical School, Chicago, Ill., January 1998.
67. Harms of screening. Workshop on thyroid cancer screening and health implications of exposure to radioactive iodine fallout. Institute of Medicine, Washington DC, March 1998.

68. Colon cancer in Ireland; is it time to screen? Mater Misericordiae Hospital and University College Dublin, Dublin Ireland, March 1998.
69. The relevance of quality of life assessment. IBD at the end of the century: facts and perspectives. Lake Garda, Italy. April 1998.
70. Colon cancer screening in the 1990s. The 1998 Gerald I. Plitman Distinguished Visiting Professor, Univ. of Tennessee, Memphis, Tenn. April 1998.
71. Quality of endoscopy in the US: What do we know? What would we like to know? Colonoscopy, Colitis, and Cancer, Nottingham, England. June 1998.
72. Health policy implications of virtual colonoscopy. First international symposium on virtual colonoscopy. Boston University School of Medicine, Boston, Mass. October 1998.
73. The researcher, the journal, and the news media. Clinical Scholars Program national meeting, Ft. Lauderdale, Florida, November 1998.
74. Economic impact of surveillance. Workshop on endoscopic research priorities. National Institutes of Health, Bethesda MD, December 1998.
75. Clinical science and the colon cancer screening controversy. Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, January 1999.
- 76.* Clinical significance of distal colonic adenomas: the controversy and the methodological issues. (with TR Levin, Tom Imperiale, and T Read) American Gastroenterological Assn., national meeting, Orlando, FL, May 1999.
- 77.* How the fields of science and law differ in assessing cause-effect relationships: lessons from the breast implant controversy. (with Stuart Bondurant, Corinne Houpt, and Walter Wadlington) Clinical Scholars Program national meeting, Ft. Lauderdale, Florida, November 1999.
78. Colon cancer in 2000. Rammelkamp Visiting Professor, Department of Medicine, Cleveland Metropolitan General Hospital, Case Western Reserve University School of Medicine, Cleveland OH, January 2000.
79. Quality of sigmoidoscopy screening. National Cancer Institute, Rockville MD. March 2000.
80. Challenges in implementation of colon cancer screening. Kansas University-Wichita, Wichita KS, March 2000.

- 81.* Controversies in screening for cancer of breast, colon, and prostate. (with Michael Barry and Joanne Elmore) American College of Physicians, national meeting, Phila. PA, April 2000.
- 82.* Do we need a randomized clinical trial of colonoscopy screening? Policy choices and methodological issues. (with Wendy Atkin, David Lieberman, and Sid Winawer) American Gastroenterological Assn., national meeting, San Diego CA. May 2000.
83. Economic issues in colon cancer screening: cost and efficacy. American Gastroenterological Assn., national meeting, San Diego CA. May 2000.
84. Development of molecular markers for colon cancer screening. University of Washington, Seattle, WA, October 2000.
- 85.* Professional guidelines, clinical science, and politics. (with Rick Deyo, Suzanne Fletcher, and Barry Kramer) Clinical Scholars Program national meeting, Ft. Lauderdale, Florida, November 2000.
86. a. Validity of surrogate outcomes in studies of colon cancer screening.
b. Roundtable discussion: status of current research, and strategies in colon cancer screening. National Cancer Institute, Bethesda, MD. March 2001.
87. Do we need a randomized clinical trial of colonoscopy screening? Cancer Research Foundation of America. Bethesda, MD. March 2001.
88. Colon cancer screening. American Society of Clinical Oncology national meeting; San Francisco, CA. May 2001.
89. Developing a training program for clinical research. Clinical Research Task Force, Washington University, St. Louis, MO. June 2001.
90. Developing molecular markers to screen for colon cancer. National Cancer Institute, Rockville, MD. October 2001.
91. Bridging clinical epidemiology and molecular biology - developing molecular markers to screen for colon cancer. University of Michigan, Ann Arbor MI. October 2001.
92. Challenges in validating molecular markers for colon cancer screening. Genomics and bioinformatics workgroup, MD Anderson Cancer Center, Houston TX. February 2002.
- 93.* Screening and prevention of colon cancer (moderator). American College of Physicians national meeting, Philadelphia PA. April 2002.

94. Need for colonoscopy screening: Now and in the future. American Gastroenterological Assn., national meeting, San Francisco. May 2002.
95. Update on colon cancer screening: Implications for national policy. American Gastroenterological Assn., national meeting, San Francisco. May 2002.
96. Quality assurance in colon cancer screening. American Cancer Society/UICC workshop, Oslo, Norway. June 2002.
97. Genomics and proteomics in early diagnosis of cancer: Challenges and opportunities in design and analysis of research. National Cancer Institute, Division of Cancer Prevention. Rockville MD. October 2002.
98. Colonoscopy - a realistic screening tool? European School of Oncology. Rome, Italy. October 2002.
99. Colon cancer screening and surveillance. American College of Physicians national meeting, San Diego, CA. April 2003.
100. Colon cancer screening: state of the art. Kaiser Permanente 2003 National Gastroenterology Conference, Sonoma, CA. April 2003.
101. Assessing serum proteomics to diagnose colon cancer. Oregon HSU, Portland OR. May 2003.
102. Three projects to assess serum proteomics to diagnose colon cancer. National Cancer Institute, Biometric Research Branch, Bethesda MD, June 2003.
103. The future of cancer diagnosis. National Cancer Policy Board, Institute of Medicine, Washington DC. June 2003.
104. Assessing serum proteomics to diagnose colon cancer. Department of Biostatistics, MD Anderson Cancer Center, Houston TX. June 2003.
105. NCI's Early Detection Research Network: A project to assess serum proteomics to screen for colon cancer. Steering Committee, Early Detection Research Network, Pittsburgh PA. June 2003.
106. Assessing molecular markers to screen for colon cancer. National Cancer Institute, Bethesda MD. September 2003.
107. Developing molecular markers to screen for cancer. 25th Anniversary, Montreal Cancer Centre, Montreal Quebec. September 2003.
108. Colon cancer screening. North American Menopause Society. Miami FL, September 2003.

109. Is virtual colonoscopy ready to be a CRC screening test? 4th International Conference on Virtual Colonoscopy. Boston MA, October 2003.
110. Utilization of colon cancer screening and surveillance: underuse and overuse. American Assn. of Cancer Research. Phoenix AZ, October 2003.
111. Methodologic problems (overfitting and others) in evaluating molecular markers for cancer. Biometry Research Group, National Cancer Institute, Rockville MD, December 2003.
112. Has proof of principle been demonstrated for serum proteomics pattern-recognition technology to diagnose cancer? National Cancer Institute Early Detection Research Network workshop on the analysis of proteomic spectral data including SELDI/MALDI-TOF-MS applications, Fred Hutchinson Cancer Research Center, Seattle WA. March 2004.
113. Colon cancer screening. American College of Physicians national meeting, New Orleans, LA. April 2004.
114. Current state of the art: Clinical aspects of validation of biomarkers. Translational cancer prevention workshop, CHS National Cancer Control Center meeting, Haifa, Israel. May 2004.
115. Biomarkers in screening. Educational conference on cancer prevention, CHS National Cancer Control Center. Dead Sea, Israel. May 2004.
- 116.* Post-colonoscopy surveillance--how intensive? American Gastroenterological Assn., national meeting, New Orleans. May 2004.
117. Monitoring quality and outcomes in colorectal cancer screening programmes. International Colorectal Cancer Screening Network. Royal College of Physicians, London. May 2004.
118. Novel methods for screening and early detection: Overview of screening and molecular detection. American Society of Clinical Oncology national meeting, New Orleans, LA. June 2004.
119. "Validation" in molecular marker research. National meeting of NCI's Early Detection Research Network, Rockville, MD. June 2004.
120. Screening for colon cancer. American Association for Cancer Research - Prevention. Seattle, WA. October 2004.
121. The new complexity: '-omics' research. NIH workshop (sponsor: Dr. E. Zerhouni): Moving from observational studies to clinical trials: Why do we sometimes get it wrong? Bethesda, MD. January 2005.

- *122. Proteomics: trials and tribulations. Gordon Research Conference (New Frontiers in Cancer Detection & Diagnosis). Buellton, CA. January 2005.
- 123. Validation of genomic markers. American Association for Cancer Research - Oncogenomics 2005. San Diego, CA. February 2005.
- 124. Considerations for study design and technology evaluation. Mini-symposium on serum proteomics. Board of Scientific Advisors, National Cancer Institute. Bethesda, MD. March 2005.
- 125. Evaluating molecular markers for cancer diagnosis and prognosis. Office of in vitro diagnostics (OIVD), US Food and Drug Administration. Rockville, MD. March 2005.
- 126. Evaluating molecular markers for cancer diagnosis and prognosis. Office of Preventive Oncology Colloquium, Division of Cancer Prevention, National Cancer Institute. Bethesda, MD. March 2005.
- 127. Clinical proteomics: Lessons learned, obstacles, and opportunities. Proteomic Interest Group; Steering Committee meeting, Early Detection Research Network, National Cancer Institute. Bethesda, MD. March 2005.
- 128. Improving colorectal cancer screening, delivery, utilization, and outcomes - Summary. NCI(DCCPS)/AHRQ State of the Science conference; Gaithersburg, MD. April 2005.
- 129. Colon cancer screening 2005: challenges and opportunities. St. Vincent's University Hospital; Dublin, Ireland. September 2005.
- 130. What is validation? Importance of proper study design in reducing chance and bias. American Society for Mass Spectrometry. Asilomar, CA. October 2005.
- 131. Use of biomarkers in clinical trials. Frontiers in Cancer Prevention Research. American Association for Cancer Research. Baltimore, MD. October 2005.
- 132. Methodologic challenges in developing biomarkers for diagnosis and prognosis. 58th Annual Symposium on Fundamental Cancer Research. MD Anderson Hospital. Houston, TX. October 2005.
- 133. Colon cancer screening, 2005. Royal College of Physicians of Edinburgh. Edinburgh, Scotland. November 2005.
- *134. Clinical validation of 'omics' markers for diagnosis and prognosis. Cambridge Healthtech Institute, 3rd Annual Molecular Diagnostics. San Francisco. February 2006.

135. Challenges in evaluating molecular markers as surrogates for cancer prevention. Cancer Prevention 2006. St. Gallen, Switzerland. February 2006.
136. Improving efficiency and reliability of evaluations of biomarkers for cancer. Keystone Conference: Molecular Targets for Cancer Prevention. Lake Tahoe. March 2006.
137. Biomarker validation. Institute of Medicine, National Cancer Policy Forum. National Academy of Sciences. Washington DC. March 2006.
138. Microarrays in medicine. Cambridge Healthtech Institute, 3rd Annual Molecular Diagnostics Conference. Boston. April 2006.
- *139. Post-polypectomy surveillance: current controversies. American Gastroenterological Assn., national meeting, Los Angeles. May 2006.
- *140. NIH State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control. Bethesda, MD. June 2006 (chair).
141. Proteomics and genomics in epidemiology research. European Congress of Epidemiology, Utrecht, Netherlands. June 2006.
142. Biomarker discovery and validation. American Association for Clinical Chemistry, Baltimore MD. October 2006.
143. Clinical index lesion of significance. 7th International Symposium on Virtual Colonoscopy, Boston MA. October 2006.
144. Improving the reliability and efficiency of proteomics and genomics research about diagnosis and prognosis. Frontiers in Cancer Prevention Research. American Association for Cancer Research. Boston MA. November 2006.
145. Serum proteomics to diagnose CRC: Preliminary results of the EDNR/GLNE "Bakeoff." Gordon Research Conference - New Frontiers in Cancer Detection and Diagnosis. Ventura CA. January 2007.
- *146. Challenges and opportunities in understanding 'omics' data about diagnosis and prognosis. Oncogenomics 2007: Dissecting Cancer Through Genome Research - American Association for Cancer Research. Phoenix AZ. February 2007.
147. Challenges and opportunities in using 'omics' technology for cancer diagnosis and prognosis. The 20th Ben Abelson Memorial Lecture. Washington University. St. Louis MO. April 2007.
148. Screening for colon cancer 2007. University of Chicago, Department of Medicine. Chicago IL. April 2007.

149. Screening for colon cancer 2007. University of Texas Southwestern Medical Center, Department of Medicine. Dallas TX. May 2007.
150. Challenges and opportunities in 'omics' research about 'individualization of medical treatment.' Harvard Department of Biostatistics/Schering-Plough Conference. Boston MA. May 2007.
151. a. Genomic signatures for breast cancer; ready for primetime?
b. Use of surrogate markers in studies of cancer prevention.
c. Challenges and opportunities in evaluating molecular markers for cancer. American Society for Clinical Oncology. Chicago IL. May 2007.
152. Discovery technology. 3rd. Haifa Cancer Prevention Workshop, CHS National Cancer Control Center. Haifa, Israel. October 2007.
153. Lost in translation: challenges and opportunities in research about molecular markers for cancer diagnosis and prognosis. Weizmann Institute of Science. Rehovot, Israel. October 2007.
154. 'Chaos in the brickyard': Translational research in 2007. Inaugural seminar in new NIH seminar series ('Mind the gap'). Bethesda, MD. November 2007.
155. Future research opportunities: Summary comments': Barrett's Esophagus Translational Research (BETR) Working Group. Bethesda, MD. January 2008.
156. Improving efficiency and reliability of evaluations of biomarkers for cancer: Status in 2008. Keystone Conference on Biomarker Discovery, Validation and Applications. Lake Tahoe, CA. February 2008.
157. Promises and limitations of biomarkers. Cancer Prevention 2008. St. Gallen, Switzerland. February 2008.
158. Role of classification systems in colon neoplasia. International Workshop on Nonpolypoid mucosal colorectal neoplasia. Kyoto, Japan. February 2008.
159. The role of biospecimens in biomarker research: Challenges and opportunities. Biospecimen Research Network Symposium. Washington DC. March 2008.
160. Current challenges in biomarker discovery and validation. Early Detection Research Network. Bethesda MD. March 2008.
161. Developing molecular biomarkers for cancer. American Association for Clinical Chemistry 21st Annual San Diego Conference: Genomics technologies at the interface of diagnostics and therapeutics. San Diego CA. March 2008.

162. Combining trials and observational data: Epidemiologic perspective. Harvard Department of Biostatistics/Schering-Plough Conference. Boston MA. May 2008.
163. Application of New Biologic Markers to Population-Level Screening and Early Detection Research Network Update. ICSN International Cancer Screening Network (NCI). Helsingor, Denmark. June 2008.
164. Quality guidelines for colon cancer screening. ICRCN International Colorectal Cancer Screening Network. Oxford UK. September 2008.
165. Challenges and opportunities in developing biomarkers for cancer diagnosis and prognosis. Biochemical Science Division. National Institute of Standards and Technology. Gaithersburg MD. November 2008.
166. Why is biomarker discovery research weak and not reproducible? Role of specimens. NCI Biometry Research Group. Bethesda MD. December 2008.
167. How can we assess the clinical validity and utility of genome profiles in risk assessment and control of colorectal cancer? Personal Genomics: Establishing the scientific foundation for using personal genome profiles for risk assessment, health promotion, and disease prevention. NCI/CDC/NHLBI. Bethesda MD. December 2008.
168. Great teachers -- Evidence-based medicine: A story of evidence, policy, and politics. NIH Clinical Center Grand Rounds. Bethesda MD. January 2009.
169. Why is biomarker discovery research weak and not reproducible? Role of specimens. NCI Biomedical Informatics and Information Technology Group. Bethesda MD. February 2009.
170. Guideline development: history; and future for ACS. American Cancer Society Board of Directors subcommittee. Atlanta GA. March 2009.
171. Research to discover biomarkers for cancer diagnosis and prognosis: challenges and opportunities. Broad Institute of MIT/Harvard. Cambridge MA. April 2009.
172. Innovations in screening and detection. Colorectal Cancer Association of Canada. Vancouver BC. April 2009.
173. Challenges in biomarker development and assessment. 3rd Annual FDA/DIA Statistics Forum, Emerging and Strategic Issues in Drug Development: Personalized Medicine and Guidance Updates. Arlington VA. April 2009.
174. Experimental design and biospecimens. NCI Board of Scientific Advisors. Bethesda MD. June 2009.

- *175. Use of specimens in NCI's cancer human biobank (caHUB). National Cancer Institute. Bethesda MD. September 2009.
- 176. Colorectal cancer screening guidelines. Kaiser-Permanente National Gastroenterology Conference. San Diego CA. October 2009.
- *177. Assessing biomarkers for cancer. Nature Publishing Group, Landscape Meeting. New York. December 2009.
- 178. Improving cancer screening research: what are the main lessons? American Association for Cancer Research. Houston TX. December 2009.
- 179. Ensuring quality in colorectal cancer screening: avoiding misuse and overuse. NIH State-of-the-Science Conference. Enhancing use and quality of colorectal cancer screening. Bethesda MD. February 2010.
- 180. How to reduce false positive study results due to bias. Association for Mass Spectrometry Applications to the Clinical Lab (MSACL). San Diego CA. February 2010.
- 181. The role of "phases" in developing biomarkers for cancer detection. FDA/CDRH (US Food and Drug Administration; Center for Devices and Radiological Health). Silver Spring MD. March 2010.
- 182. Evidence-based medicine and CRC screening guidelines: science, policy, and politics. GI Division, University of Pennsylvania. March 2010.
- 183. Research about molecular markers for cancer: challenges and opportunity (opportunity for clinical epidemiologists). Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania. March 2010.
- 184. Clinical proteomics to detect cancer: lessons from the last 10 years (closing keynote). Wellcome Trust - Perspectives in Clinical Proteomics Conference. Cambridge UK. March 2010.
- 185. Exploring the limits of colorectal cancer screening. Dialogue for Action on Colorectal Cancer Screening. Baltimore MD. March 2010.
- 186. Challenges and opportunities in translational "-omics" research. Association for Clinical Research Training/Society for Clinical and Translational Science, national meeting. Washington DC. April 2010.
- 187. Future directions of DCCPS. NCI's DCCPS (Division of Cancer Control and Population Sciences) think-tank retreat. Rockville, MD. June 2010.

188. Biomarkers for cancer screening - Workshop Report. International Cancer Screening Network (NCI), Oxford, UK. June 2010.
189. Translating genomic-based research for health: Chain of evidence. Institute of Medicine. Washington DC. Nov 2010.
190. NCI Director's "Provocative Questions" meeting: Overdiagnosis. Bethesda MD. Feb 2011.
191. Bias and artifacts in molecular marker research. International Conference on Breast Cancer. Muscat, Oman. Feb 2011.
192. Molecular markers for cancer: Problems and promise. Albert Einstein College of Medicine. New York NY. Feb 2011.
193. Proteomics research and cancer screening. Lessons from the first 10 years. national meeting, US Human Proteomics Organization. Raleigh NC March 2011.
194. Implementation - pilot testing - and further development: A critical next step. Institute of Medicine (Committee on standards for developing trustworthy clinical practice guidelines). Washington DC May 2011.
195. Proteomics research and cancer screening: The first 10 years. International Human Proteome Organization meeting. Geneva, Switzerland. September 2011.
196. Bias and artifacts in tumour molecular marker research. Controversies in breast cancer 2011. Edinburgh, UK. September 2011.
197. Translational CRC research: State of the art 2011. Danish Cancer Society. Copenhagen, Denmark. September 2011.
198. Evidence-based medicine and CRC screening: evidence, policy, and politics. Columbia Univ. College of Physicians and Surgeons. New York. February 2012.
199. Defining molecularly-informed natural history of occult neoplasms. National Cancer Institute, Division of Cancer Prevention. Rockville MD. March 2012.
- *200. Problems of culture clash when basic and clinical researchers collaborate. American Association for Cancer Research natl. meeting. Chicago. March 2012.
201. IOM (Institute of Medicine) report on standards for developing "trustworthy" clinical practice guidelines. American Association for Cancer Research natl. meeting. Chicago. March 2012.
- *202. NC Biotechnology Forum: Biomarkers: Applications for Personalized Medicine. Research Triangle Park, NC. April 2012.

203. New Diagnostics and Devices: Evaluating new technologies for diagnosis and prognosis. American Society for Clinical Oncology. Chicago. June 2012.
204. Trends in 21st Century Epidemiology. National Cancer Institute. Bethesda. December 2012.
205. Challenges in implementing personalized surgical care when the science isn't ready. Society of Surgical Oncology. Washington DC. March 2013.
206. Developing Molecular Markers for Colon Cancer Screening. World Endoscopy Organization. Orlando FL. May 2013.
207. The American Cancer Society's Next 100 Years: Challenge and Opportunity. American Cancer Society 100th Year Celebration. Atlanta GA. May 2013.
207. Cancer screening tests: why promise and disappointment? Some lessons from last 10+ years. Stanford University. Stanford CA. May 2013.
208. Omics Research for Diagnosis and Prognosis: Challenges and Opportunities. Waisman Center, University of Wisconsin. Madison WI. June 2013.

* = moderator or organizer